Telix Pharmaceuticals price target lowered to $22 from $22.50 at Citi
Citi lowered the firm's price target on Telix Pharmaceuticals to $22 from $22.50 and keeps a Buy rating on the shares. Q2 Visible Alpha consensus of $184M in Illuccix/Gozellix sales "looks reasonable," says the analyst, who thinks a 5%-plus beat would "bring into view" a potential FY26 guidance upgrade, though the firm